If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
You need a JavaScript-enabled browser to view this Publication
Please follow these steps to view the Publication:
Enable JavaScript in your browser
Refresh this page
Best regards
Zmags
Ipls Proceedings
State Bar of Michigan
Volume 32 • Issue 1 • 2021
In This Issue
View from the Chair ........................... 1
Call For Attorneys to get Involved
in Our Pro Bono Initiatives ........... 2
Reflections on the State Bar’s
Relationship with Technology
in Response to COVID-19 ........... 3
Exploring the Interfaces Between
Big Data and Intellectual
Property Law ................................ 5
Bayh-Dole and March-In Mischief:
Why Congressional Action
is Needed to Protect and
Promote Pharmaceutical
Innovation .................................. 21
Scenes from Our 2019-2020
In-person Meetings .................... 33
View from the Chair
Members,
As 2020 has slllooowlllly drawn t
Ipls Proceedings State Bar of Mi
Intellectual Property Law Section 2020-2021 Of
Reflections on the State Bar’s Relationship with
Bar associations should be thinking about t
Exploring the Interfaces Between Big Data and Int
and surveillance, though an almost endless array
“deserve” a patent despite their obviousness (to
copyright in what one might call the “organizatio
Public License (GPL) model, which uses copyright
matic analysis of large numbers of works (source
maintains the TDM exception for scientific resear
three-step test’s second step.88 The Second Circu
which would remain patentable, therefore, when an
most computer programs are unlikely to pass.115 T
Moreover, its use may no longer be limited by the
9 Cassie Kozyrkov, ‘Are you using the term ‘AI’
infocus.dellemc.com/april_reeve/big-data-and-nosq
European Commission, ‘Staff Working Documen
91 Panel Report, paras 6.223–6.229. In para. 6.2
(2018) 24 Richmond J.L. & Technolo
Bayh-Dole and March-In Mischief: Why Congressiona
ment, commentators and policymakers alike have ch
tor” in these preliminary-stage drugs, the taxpay
Bush proposal and the DOJ report halfway, the age
Administration (“FDA”) trials, a process that ind
The most problematic of the statutory crite
[B]ecause the market dynamics for all prod
have cloaked its price-control within the ambiguo
would technically own the right to relicense the
ing both investor wallets and patience. Mischarac
Bell, supra note 4, at 494; Sean O’Con
80 Thomas, supra note 73. 81 Id. 82 Id.
Scenes from Our 2019-2020 In-person Meetings
We’ll be back some day!